Optimising Treatment of HF

Published: 21 April 2021

  • Views:

    Views Icon 18435
  • Likes:

    Heart Icon 7


Full programme

Part 4 of 5

PART 4 – Existing HF-REF: Augmenting the SOC

Shelley Zieroth

Download Slides


Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.


Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases


  • Heart Failure Specialists
  • General Cardiologists
  • Nurses
  • Allied Health Professionals

More from this programme

Part 1

PART 1 – Introduction – Optimising Treatment of HF

Prof Martin Cowie introduces the topic, and reviews the learning objectives of the programme.

Part 2

PART 2 – A Review of Recent SGLT2 Inhibitor Data

Prof Giuseppe Rosano reviews recent SGLT2 trial data, including DAPA – HF, and Emperor Reduced.

Part 3

PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

Dr Javed Butler presents a case, and considers available treatment strategies, and the optimal approach for HFrEF medications.

Part 4

PART 4 – Existing HF-REF: Augmenting the SOC

Dr Shelley Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.

Part 5

PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?

Prof Cowie moderates a discussion with the faculty.

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

University of Manitoba, Canada

Dr Shelley Zieroth is at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

Dr Zieroth attended medical school at the University of Manitoba, where she went on to train in internal medicine and cardiology. She completed her postdoctoral clinical fellowship, specializing in advanced heart failure and cardiac transplant, at Toronto General Hospital. Dr Zieroth has lectured internationally on the subject of heart failure.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile